Prader-Willi syndrome

Overview

Prader-Willi syndrome is a rare genetic condition that affects multiple body systems and presents with a characteristic pattern of features that evolve as a child grows. The condition is present from birth but the clinical picture changes markedly over time. In the newborn period, affected infants typically display profound hypotonia (floppiness) and feeding difficulties requiring specialist support. From early childhood onwards, a hallmark feature emerges: hyperphagia, an insatiable appetite driven by dysfunction in the brain's satiety mechanisms, which without careful management leads to severe obesity and associated complications.

The condition was first described in 1956 by Swiss physicians Prader, Labhart and Willi, who recognised a consistent pattern of features in children with unexplained obesity and developmental delay. Research over subsequent decades has revealed that Prader-Willi syndrome results from loss of expression of a cluster of genes normally active only on the chromosome 15 inherited from the father. This makes it an example of a genomic imprinting disorder, where the parent of origin of a genetic change determines whether disease occurs.

Prevalence is estimated at approximately 1 in 10,000 to 30,000 births, though exact figures vary between studies, making it one of the more common genetic causes of life-threatening obesity in childhood. The condition affects males and females equally and occurs across all ethnic groups. Early diagnosis through genetic testing enables families to access specialist care pathways and implement management strategies that can significantly improve outcomes and quality of life.

Symptoms & clinical features

Clinical features of Prader-Willi syndrome follow a recognisable trajectory across different life stages. During the neonatal period and infancy, the predominant concern is severe hypotonia, often described as a 'floppy' baby. Affected newborns have weak muscle tone, reduced movement, a weak cry, and significant feeding difficulties due to poor suck reflex. Many require tube feeding in the early months. Growth in infancy is typically slow, and developmental milestones such as sitting, crawling and walking are delayed.

From approximately 18 months to 6 years of age, a dramatic shift occurs. The child develops an excessive interest in food and an inability to feel full after eating. This hyperphagia is not simply increased appetite but represents a fundamental dysfunction in the hypothalamic circuits that normally signal satiety. Without environmental controls on food access, affected children will eat continuously and may engage in food-seeking behaviours such as scavenging, hoarding or eating inappropriate items. This phase coincides with rapid weight gain that, if unmanaged, progresses to severe obesity.

Beyond the appetite and weight concerns, individuals with Prader-Willi syndrome typically have mild to moderate learning difficulties, though the range is wide and some have borderline to low-average intelligence. Behavioural characteristics often include stubbornness, temper outbursts, obsessive or compulsive traits, and difficulty with transitions or changes in routine. Sleep disturbances are common, including excessive daytime sleepiness and sleep apnoea. Many individuals have delayed puberty, incomplete sexual development, and are infertile due to hypogonadism. Short stature is characteristic, related both to growth hormone deficiency and the underlying genetic changes. Distinctive facial features may be present but are often subtle, including narrow forehead, almond-shaped eyes, and a thin upper lip.

Video: Genetics 101

Affected organs

The hypothalamus, a small but critical region at the base of the brain responsible for regulating appetite, body temperature, sleep-wake cycles and hormone production, is the primary site of dysfunction in Prader-Willi syndrome. Disruption of hypothalamic pathways explains many core features: the insatiable appetite arises from impaired satiety signalling, temperature instability can occur particularly in infancy, and deficient production of hormones that stimulate the pituitary gland leads to growth hormone deficiency and hypogonadism.

Obesity resulting from hyperphagia has secondary effects on multiple organ systems. The cardiovascular system may be affected by hypertension and increased risk of heart disease. Type 2 diabetes develops in many individuals, reflecting both the metabolic consequences of obesity and possible intrinsic insulin resistance. The respiratory system is affected through obesity-related breathing difficulties and obstructive sleep apnoea, which can be severe. The musculoskeletal system bears the burden of excess weight, with increased risk of scoliosis (spinal curvature) and orthopaedic problems. The endocrine system shows widespread dysfunction beyond the hypothalamic-pituitary axis, including altered stress hormone responses and disrupted regulation of body composition, with affected individuals having increased fat mass and reduced muscle mass even relative to their degree of obesity.

Multiple body systems

Systemic involvement

Cellular impact

Mechanism at cellular level

Risks & severity

Severity of Prader-Willi syndrome varies between individuals but all affected people require lifelong support and careful management of food intake. The most significant health risk is severe obesity and its complications. Without strict dietary control and environmental management to prevent unrestricted food access, life-threatening obesity develops in virtually all cases. Historical studies suggested reduced life expectancy in inadequately managed cases, but modern multidisciplinary care has substantially improved outcomes, with many individuals now living into later adulthood when obesity is well-controlled. Obesity-related complications including type 2 diabetes, cardiovascular disease, sleep apnoea and respiratory failure remain important health risks.

The risk of acute complications includes gastric distension or rupture, which can occur if individuals gain access to large quantities of food and overeat to a dangerous degree. This is a medical emergency and can be fatal. Behavioural and psychiatric challenges increase with age, and while not life-threatening, these significantly impact quality of life for affected individuals and their families. The combination of learning difficulties, obsessive tendencies, and emotional dysregulation requires ongoing behavioural support. Most adults with Prader-Willi syndrome require supported living arrangements and are unable to live independently due to the need for constant supervision of food access and support with daily living skills. Early diagnosis, growth hormone treatment in childhood, and comprehensive multidisciplinary care substantially improve outcomes, enabling many individuals to achieve better health, functional abilities and participation in their communities.

Genetic causes

Prader-Willi syndrome results from loss of function of a group of genes located in a specific region of chromosome 15, designated 15q11-q13. Humans inherit two copies of chromosome 15, one from each parent, but the genes in this particular region show parent-of-origin-specific expression through a mechanism called genomic imprinting. Several genes in the 15q11-q13 region are normally active only on the paternally inherited chromosome 15, whilst being silenced on the maternal copy. Prader-Willi syndrome occurs when these paternally expressed genes are absent or non-functional.

Three distinct genetic mechanisms account for cases. Approximately 65-75% of individuals have a deletion of the 15q11-q13 region on the chromosome 15 inherited from their father. This removes the only active copies of the relevant genes, since the maternal copies are already silenced by imprinting. Around 20-30% of cases result from maternal uniparental disomy, where a person inherits two copies of chromosome 15 from their mother and none from their father. Although two chromosome 15s are present, both copies have the maternal imprinting pattern, so the genes that should be active on the paternal chromosome are silenced on both copies. A small percentage of cases result from imprinting defects, where the paternal chromosome 15 is present but carries an incorrect (maternal) imprinting pattern, again silencing the genes that should be expressed.

The protein products of genes in this region contribute to hypothalamic development and function, though the precise roles of individual genes continue to be investigated. The overall effect of losing paternal gene expression is disruption of neural circuits controlling appetite, growth, metabolism and behaviour. Interestingly, loss of the same chromosomal region from the maternally inherited chromosome 15 causes a different condition, Angelman syndrome, which has distinct clinical features. This demonstrates that different genes in this region are active depending on which parent the chromosome came from.

Inheritance pattern

Prader-Willi syndrome is genetic (caused by changes in DNA) but usually sporadic, meaning it occurs for the first time in the affected individual and is not inherited from parents in the traditional sense. The vast majority of cases represent new (de novo) genetic events, with parents having a very low recurrence risk for future pregnancies.

When Prader-Willi syndrome results from a deletion of the paternal 15q11-q13 region or from maternal uniparental disomy, these events typically occur randomly during formation of egg or sperm cells or in early embryonic development. Parents of an affected child usually have normal chromosomes, and the recurrence risk for subsequent pregnancies is typically well under 1%, only slightly above the background population risk. Genetic counselling can provide families with personalised risk assessment and discuss options for prenatal testing in future pregnancies if desired.

Rare familial cases can occur, particularly with imprinting defects. Some imprinting defects are caused by small deletions in the imprinting control region that can be inherited. If a father carries such a deletion, there is up to a 50% chance of passing it to his children, who would then have Prader-Willi syndrome. For this reason, when an imprinting defect is identified in a child, parental testing is recommended to determine whether it is inherited or de novo, as this substantially affects recurrence risk. Occasionally, a parent may carry a balanced chromosomal rearrangement involving chromosome 15 that increases the risk of an unbalanced chromosome 15 in offspring, though this is uncommon. Overall, most families affected by Prader-Willi syndrome face a low recurrence risk, but genetic counselling is important to clarify the specific mechanism and provide accurate information.

Diagnosis & testing

Prader-Willi syndrome should be suspected in any infant with unexplained hypotonia and feeding difficulties, or in any child who develops excessive weight gain and hyperphagia following a history of neonatal hypotonia. The diagnosis is confirmed through genetic testing, specifically DNA methylation analysis of the 15q11-q13 region. This test can detect the absence of the normal paternal methylation pattern regardless of which of the three mechanisms is responsible, making it an excellent first-line diagnostic test with very high sensitivity, generally exceeding 99%.

If methylation testing confirms Prader-Willi syndrome, additional genetic studies are typically performed to determine the specific underlying mechanism. Fluorescence in situ hybridisation or chromosomal microarray can identify deletions of the 15q11-q13 region. If no deletion is found, further testing can distinguish between maternal uniparental disomy (usually identified by DNA marker studies examining the parental origin of chromosome 15) and an imprinting defect. Determining the mechanism is important for recurrence risk counselling, as discussed above.

In the UK, genetic testing for suspected Prader-Willi syndrome is accessed through referral to Clinical Genetics services or may be initiated by paediatricians in close liaison with genetics. The condition is included in NHS England's National Genomic Test Directory. Following diagnosis, comprehensive clinical assessment is arranged to evaluate the range of features present and establish baseline measurements for growth, development, metabolic parameters and other relevant factors. Referral to a specialist Prader-Willi syndrome clinic, where available, ensures access to the multidisciplinary expertise needed for optimal management. Early diagnosis is valuable because it enables prompt implementation of dietary management, consideration of growth hormone therapy, and access to appropriate developmental and educational support.

Management & lifestyle

Management of Prader-Willi syndrome requires a coordinated multidisciplinary approach throughout life, with strategies adapted to the changing needs across different developmental stages. The cornerstone of care is strict control of food access and a structured, reduced-calorie diet to prevent obesity. From the time hyperphagia emerges, environmental controls are essential: locking kitchens and food storage areas, supervising all meals and snacks, establishing consistent routines, and educating all caregivers about the critical importance of restricting food access. A dietitian with experience in Prader-Willi syndrome can develop an individualised eating plan that provides adequate nutrition whilst controlling calorie intake.

Growth hormone treatment, started in early childhood, has become standard care and improves multiple outcomes. Evidence suggests it increases height, improves body composition by increasing muscle mass and reducing fat mass, and may have beneficial effects on motor development, cognitive function and behaviour. Treatment is typically continued through childhood and adolescence, with some individuals continuing into adulthood. Endocrine input is important to monitor growth hormone therapy and to address other hormonal deficiencies such as hypogonadism and hypothyroidism when present. Sex hormone replacement may be considered during the expected pubertal years to support development of secondary sexual characteristics, though fertility remains extremely rare.

Developmental support and educational input tailored to the individual's needs are important from early childhood. Physiotherapy helps address hypotonia and motor delays in infancy. Speech and language therapy may be needed for feeding difficulties in infancy and for communication development. Behavioural strategies and psychological support are valuable for managing the behavioural and emotional challenges that often intensify with age. Sleep disorders should be assessed and treated, as untreated sleep apnoea impacts health, behaviour and daytime functioning. Regular monitoring for complications of obesity, including screening for type 2 diabetes, cardiovascular risk factors and orthopaedic problems, enables early intervention. Transition to adult services requires careful planning to ensure continuity of the specialised care and supervision required. Genetic counselling is offered to families to explain the condition, discuss recurrence risks, and provide information about testing options for relatives where relevant. NHS care pathways link families with clinical genetics services, specialist endocrinology, and where available, dedicated Prader-Willi syndrome clinics.

UK care pathway

Within the NHS, diagnosis of Prader-Willi syndrome typically occurs following referral to paediatric services for investigation of neonatal hypotonia or developmental concerns, or to Clinical Genetics services when the diagnosis is suspected based on clinical features. Genetic testing is accessed through the NHS Genomic Medicine Service, with Prader-Willi syndrome included in the National Genomic Test Directory under appropriate indications such as hypotonia or syndromic obesity. Following genetic confirmation, families are referred to specialist services which may include regional Prader-Willi syndrome clinics where these exist, bringing together expertise from paediatric endocrinology, dietetics, clinical genetics, developmental paediatrics and other relevant disciplines.

Genetic counsellors play an important role in supporting families following diagnosis, explaining the genetic mechanisms in accessible terms, clarifying implications for other family members, and discussing reproductive options and prenatal testing for future pregnancies. The multidisciplinary team approach ensures comprehensive assessment and coordinated care plans addressing the medical, developmental, behavioural and social needs of the individual and their family. As affected individuals transition to adulthood, appropriate handover to adult services is arranged, often involving adult endocrinology, psychiatry, learning disability services and supported living teams. Ongoing research continues to refine management approaches, and families may be informed about relevant clinical studies through their specialist centres. Patient support organisations provide valuable resources, peer support and advocacy for families affected by Prader-Willi syndrome.

Related conditions

Several conditions share phenotypic overlap with Prader-Willi syndrome and may be considered in the differential diagnosis, particularly in the early stages before the full clinical picture has emerged. Neonatal hypotonia with feeding difficulties occurs in many genetic and non-genetic conditions, including other chromosomal disorders, neuromuscular conditions, and metabolic diseases. When hyperphagia and obesity develop, other genetic obesity syndromes warrant consideration. Bardet-Biedl syndrome shares features of obesity, learning difficulties and hypogonadism, but is distinguished by additional features including retinal dystrophy, polydactyly and renal abnormalities, and has a different genetic basis with autosomal recessive inheritance.

Angelman syndrome, though clinically distinct, merits mention because it results from loss of function of different genes in the same chromosomal region as Prader-Willi syndrome, but from the maternally inherited chromosome 15 rather than the paternal copy. Angelman syndrome presents with severe developmental delay, absent speech, movement disorder, and a characteristic happy demeanour, contrasting with the phenotype of Prader-Willi syndrome. Recognising this relationship highlights the importance of parent-of-origin effects in the 15q11-q13 region. Other conditions in the differential for childhood obesity with developmental delay include fragile X syndrome, Cohen syndrome, and WAGR syndrome, each with distinctive additional features and different genetic causes. Accurate genetic diagnosis through comprehensive testing ensures families receive appropriate information about prognosis, management and recurrence risk, and enables access to condition-specific care pathways and support networks.

Frequently asked questions

References

1. Cassidy SB. Prader-Willi syndrome. Current problems in pediatrics. 1984. PMID: 6365470
2. Couper R. Prader-Willi syndrome. Journal of paediatrics and child health. 1999. PMID: 10457284
3. Godler DE, Butler MG. Special Issue: Genetics of Prader-Willi Syndrome. Genes. 2021. PMID: 34573411
4. Ryabinin AE. Focus on autism and other neurodevelopmental disorders. Genes, brain, and behavior. 2022. PMID: 34891220
5. Mooney LN, Dominick KC, Erickson CA. Psychopharmacology of neurobehavioral disorders. Handbook of clinical neurology. 2019. PMID: 31727225
6. Wattendorf DJ, Muenke M. Prader-Willi syndrome. American family physician. 2005. PMID: 16156341
7. Zahova S, Isles AR. Animal models for Prader-Willi syndrome. Handbook of clinical neurology. 2021. PMID: 34238473
8. Spencer DA. Prader-Willi syndrome. Lancet (London, England). 1968. PMID: 4175418